|Articles|February 11, 2016
Biotech Selects Almac's Interactive Response Platform
A global biotech will be migrating to its newest generation Interactive Response Technology (IRT), platform for the upcoming build of 15 clinical studies across multiple therapeutic areas in early 2016.
Advertisement
Almac Clinical Technologies, part of the Almac Group, has announced that a global biotechnology company will be migrating to its newest generation Interactive Response Technology (IRT), IXRS® 3 platform for the upcoming build of 15 clinical studies across multiple therapeutic areas in early 2016.
Read the
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Lab Orchestration Is Not What You Think It Is
2
Why Seizure Counts Alone Can't Define Success in Epilepsy Trials
3
ACT Brief: Patient Voice in Protocol Design, AI-Informed Recruitment Workflows, and Engagement Maturity Beyond Performative
4
What It Actually Means to Embed the Patient Voice in Trial Design
5